JP4588791B2 - 微粒子油性懸濁液を含む医薬組成物 - Google Patents

微粒子油性懸濁液を含む医薬組成物 Download PDF

Info

Publication number
JP4588791B2
JP4588791B2 JP2008558013A JP2008558013A JP4588791B2 JP 4588791 B2 JP4588791 B2 JP 4588791B2 JP 2008558013 A JP2008558013 A JP 2008558013A JP 2008558013 A JP2008558013 A JP 2008558013A JP 4588791 B2 JP4588791 B2 JP 4588791B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
suspension
pharmaceutical
average particle
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008558013A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2008099615A1 (ja
Inventor
泰紀 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of JPWO2008099615A1 publication Critical patent/JPWO2008099615A1/ja
Application granted granted Critical
Publication of JP4588791B2 publication Critical patent/JP4588791B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008558013A 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物 Expired - Fee Related JP4588791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007035916 2007-02-16
JP2007035916 2007-02-16
PCT/JP2008/000230 WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010040362A Division JP2010120974A (ja) 2007-02-16 2010-02-25 微粒子油性懸濁液を含む医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2008099615A1 JPWO2008099615A1 (ja) 2010-05-27
JP4588791B2 true JP4588791B2 (ja) 2010-12-01

Family

ID=39689861

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008558013A Expired - Fee Related JP4588791B2 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物
JP2010040362A Pending JP2010120974A (ja) 2007-02-16 2010-02-25 微粒子油性懸濁液を含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010040362A Pending JP2010120974A (ja) 2007-02-16 2010-02-25 微粒子油性懸濁液を含む医薬組成物

Country Status (9)

Country Link
US (1) US8309138B2 (enExample)
EP (1) EP2123255B1 (enExample)
JP (2) JP4588791B2 (enExample)
KR (1) KR101434706B1 (enExample)
CN (1) CN101610754A (enExample)
AU (1) AU2008215659B2 (enExample)
CA (1) CA2677842C (enExample)
ES (1) ES2423929T3 (enExample)
WO (1) WO2008099615A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof
US12703689B2 (en) 2017-08-17 2026-08-11 University Of Delaware Furan based compositions and methods of making thereof
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (en) 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー．ディー．サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
RU2186562C2 (ru) 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
NZ501112A (en) 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
KR20010040646A (ko) 1998-02-09 2001-05-15 블로닉, 조엘 위장관의 만성 염증성 질환의 치료방법
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
JP2002533378A (ja) * 1998-12-23 2002-10-08 アムジエン・インコーポレーテツド タンパク質の徐放用ポリオール／油懸濁液
KR100711538B1 (ko) 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
EP1058539A1 (en) * 1999-01-06 2000-12-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
SK286371B6 (sk) 1999-02-23 2008-08-05 Merck & Co., Inc. Farmaceutický prostriedok
IL146105A (en) 1999-04-23 2005-09-25 Tadeda Pharmaceutical Company 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
DE60016617T2 (de) 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
IN192188B (enExample) 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ES2225600T3 (es) * 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
US20030157172A1 (en) 2001-12-20 2003-08-21 Lu Guang Wei Pharmaceutical suspension for oral administration
EP1490025B1 (en) 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003255844A1 (en) 2002-08-23 2004-03-11 Ionix Pharmaceuticals Limited Five-membered heterocyclic compounds in the treatment of chronic and acute pain
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20040132755A1 (en) 2002-09-06 2004-07-08 Mark Ledeboer Isoxazoles and uses thereof
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
CA2515939A1 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2004073692A1 (ja) 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
JP5096658B2 (ja) 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
ES2392344T3 (es) * 2004-05-04 2012-12-07 Hormos Medical Ltd. Formulaciones orales líquidas de ospemifeno
ATE538118T1 (de) 2004-12-28 2012-01-15 Aska Pharm Co Ltd Pyrimidinylisoxazolderivat
JP2007039408A (ja) * 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Also Published As

Publication number Publication date
WO2008099615A1 (ja) 2008-08-21
ES2423929T3 (es) 2013-09-25
US20100092565A1 (en) 2010-04-15
JP2010120974A (ja) 2010-06-03
EP2123255A4 (en) 2010-06-02
JPWO2008099615A1 (ja) 2010-05-27
CN101610754A (zh) 2009-12-23
EP2123255B1 (en) 2013-05-15
CA2677842C (en) 2014-09-16
US8309138B2 (en) 2012-11-13
AU2008215659A1 (en) 2008-08-21
KR20090117894A (ko) 2009-11-13
AU2008215659B2 (en) 2012-11-01
KR101434706B1 (ko) 2014-08-26
CA2677842A1 (en) 2008-08-21
EP2123255A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
JP2010120974A (ja) 微粒子油性懸濁液を含む医薬組成物
ES2496144T3 (es) Formulación de cápsulas de pirfenidona y excipientes farmacéuticamente aceptables
KR101454086B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
Zhou et al. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine
ES2883448T3 (es) Composiciones farmacéuticas mejoradas de pimobendán
TW200821298A (en) Pharmaceutical compositions
JPWO2005060935A1 (ja) 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
JP7780442B2 (ja) メチル｛４，６－ジアミノ－２－［５－フルオロ－１－（２－フルオロベンジル）－１Ｈ－ピラゾロ［３，４－ｂ］ピリジン－３－イル］ピリミジン－５－イル｝カルバメートのナノ製剤
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
JP2015510935A (ja) 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法
JPWO2008015959A1 (ja) 薬理活性物質の吸収性が改善された医薬組成物
KR20120094178A (ko) 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
Zhang et al. A novel oil-based suspension of a micro-environmental, pH-modifying solid dispersion for parenteral delivery: Formulation and stability evaluation
JPWO2006073154A1 (ja) 医薬組成物及びその製造方法
JPWO2020045456A1 (ja) 薬物含有粒子
CN1615899B (zh) 葛根素口服制剂
TWI597063B (zh) 藥物組成物及其製備方法
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
JPS6136217A (ja) 経口投与用持効性製剤
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral
WO2007052738A1 (ja) 薬物の吸収性が改善された医薬組成物
JP2004519489A (ja) 薬剤組成物
JP6935987B2 (ja) 医薬組成物
JP2025502120A (ja) プロゲリニンを含む顆粒剤及びそれを用いたサシェ剤
JP2018044017A (ja) 粒子製剤

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100907

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100908

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4588791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130917

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees